Stock UNCY UNICYCIVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 10:11:52 2024-04-29 am EDT 		5-day change 1st Jan Change
1.01 USD -1.94% Intraday chart for Unicycive Therapeutics, Inc. -12.15% +16.43%
Apr. 04 Piper Sandler Initiates Coverage on Unicycive Therapeutics With Overweight Rating, $9 Price Target MT
Mar. 28 Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.

Number of employees: 14

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Therapies
100.0 %
1 100.0 % 1 100.0 % -29.02%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1 100.0 % 1 100.0 % -29.02%

Managers

Managers TitleAgeSince
Shalabh Gupta CEO
 Chief Executive Officer 51 16-08-17
John Townsend DFI
 Director of Finance/CFO 62 20-08-31
Pramod Gupta COO
 Chief Operating Officer 63 20-08-31
Douglas Jermasek PRN
 Corporate Officer/Principal 63 21-10-25

Members of the board

Members of the board TitleAgeSince
Sandeep Laumas BRD
 Director/Board Member 56 17-12-31
John Ryan BRD
 Director/Board Member 80 17-12-31
Gaurav Aggarwal BRD
 Director/Board Member 51 23-03-07
Saraswati Kenkare-Mitra BRD
 Director/Board Member 57 23-09-05
Shalabh Gupta CEO
 Chief Executive Officer 51 16-08-17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 34,756,436 28,360,425 ( 81.60 %) 0 81.60 %
Stock B 0 43,649 0 0

Shareholders

NameEquities%Valuation
Shalabh Gupta
16.89 %
5,871,726 16.89 % 8 M $
RA Capital Management LP
9.986 %
3,470,688 9.986 % 5 M $
Vivo Capital LLC
9.985 %
3,470,152 9.985 % 5 M $
Logos Global Management LP
9.984 %
3,469,927 9.984 % 5 M $
Nantahala Capital Management LLC
9.893 %
3,438,181 9.893 % 5 M $
BVF, Inc.
6.095 %
2,118,139 6.095 % 3 M $
Nantahala Capital Management LLC
5.997 %
2,084,221 5.997 % 3 M $
Rosalind Advisors, Inc.
5.408 %
1,879,646 5.408 % 3 M $
Armistice Capital LLC
2.808 %
976,000 2.808 % 1 M $
Rosalind Advisors, Inc.
2.790 %
969,484 2.790 % 1 M $
NameEquities%Valuation
Vivo Capital LLC
746.06 %
13,429,000 746.06 % 19 M $
RA Capital Management LP
611.89 %
11,014,000 611.89 % 15 M $
BVF Partners LP
6.667 %
120,000 6.667 % 165 600 $
Logos Global Management LP
0.0755 %
1,359 0.0755 % 1 875 $

Company contact information

Unicycive Therapeutics, Inc.

4300 El Camino Real Suite 210

94022, Los Altos

+

http://www.unicycive.com
address Unicycive Therapeutics, Inc.(UNCY)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.03 USD
Average target price
5.3 USD
Spread / Average Target
+414.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
UNICYCIVE THERAPEUTICS, INC. Stock Unicycive Therapeutics, Inc.
+16.43% 38.73M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.05% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+11.55% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.07% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.87% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.63% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.98% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.89% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. UNCY Stock
  4. Company Unicycive Therapeutics, Inc.